Abstract
// XuFeng Peng 1, * , Bo Hao 3, * , Nailong Cao 1 , Jihong Wang 1 , Xiangguo Lv 2 and XinRu Zhang 1 1 Department of Urology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China 2 Department of Urology and Andrology, Shanghai Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200001, China 3 Department of Cardiothoracic Surgery, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China * These authors have contributed equally to this work Correspondence to: XinRu Zhang, email: 15800558925@163.com Xiangguo Lv, email: chnlvsc@163.com Keywords: ADAM17; cancer; prognosis; lymph node metastasis; distant metastasis Received: July 15, 2017 Accepted: December 26, 2017 Published: January 02, 2018 ABSTRACT ADAM17 (a disintegrin and metalloproteinase 17) is overexpressed in many types of cancer, and its high expression in cancer patients is associated with increased risk of metastasis and a poorer prognosis. However, the clinical value of ADAM17 as a tumor biomarker remains largely unknown. In this meta-analysis, we investigated the relationships between ADAM17 levels, cancer metastasis, and patient prognosis. Twelve eligible studies involving a total of 1816 patients were identified in searches of the PubMed, Embase, Cochrane, and Chinese National Knowledge Infrastructure databases. Analysis of these studies revealed that ADAM17 overexpression is positively associated with lymph node metastasis in a fixed effect model and distant metastasis in a random effect model. Moreover, high ADAM17 expression was predictive of shorter overall and progression-free survivalof cancer patients in fixed effect models. These results suggest that ADAM17 maybe a useful biomarker for predicting metastasis and prognosis in cancer patients and may also aid in risk stratification and selection of individualized treatments.
Highlights
Cancer has become one of the most important diseases threatening human health and life [1]
ADAM17 is overexpressed in many types of cancer, and its high expression in cancer patients is associated with increased risk of metastasis and a poorer prognosis
The clinical value of ADAM17 as a tumor biomarker remains largely unknown. In this meta-analysis, we investigated the relationships between ADAM17 levels, cancer metastasis, and patient prognosis
Summary
Cancer has become one of the most important diseases threatening human health and life [1]. It is important to identify additional biomarkers that can predict prognosis and guide individualized treatments. ADAMs (a disintegrin and metalloproteinases), originally known as MDC (metalloproteinase/ disintegrin/cysteine-rich) proteins, are multi-domain membrane-anchored proteins belonging to the Metzincins superfamily of metalloproteases [5]. More than 30 ADAMs have been identified in various animal species, and some are implicated in several pathophysiological conditions [6]. ADAM17 ( known as tumor necrosis factor-alpha-converting enzyme, TACE), which cleaves the pro-inflammatory cytokine TNF-alpha from its membrane-bound precursor, is the best-characterized ADAM [7]. ADAM17 plays an important role in malignant lesionsby regulating the epidermal growth factor receptor www.impactjournals.com/oncotarget s995
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
